Extensive studies have been conducted on various inhibitors and clinical drugs targeting the PI3K-AKT pathway as RNA based cancer gene therapy, including their applications in gastrointestinal tumors (Table 3). This evidence concerns the gene PIK3CB and digestive system neoplasm.